미국 - 영어 - NLM (National Library of Medicine)

sagent pharmaceuticals - melphalan hydrochloride (unii: 1vxp4v453t) (melphalan - unii:q41or9510p) - melphalan hydrochloride for injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. melphalan should not be used in patients whose disease has demonstrated prior resistance to this agent. patients who have demonstrated hypersensitivity to melphalan should not be given the drug.

나미비아 - 영어 - Namibia Medicines Regulatory Council

pharmacare (pty) ltd - melphalan - tablets - each tablet contains melphalan 2 mg

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - melphalan, quantity: 50 mg - injection, powder for - excipient ingredients: povidone; hydrochloric acid - for the treatment of patients with multiple myeloma for whom oral therapy is not appropriate

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

emcure pharmaceuticals pty ltd - melphalan hydrochloride, quantity: 55.97 mg (equivalent: melphalan, qty 50 mg) - injection, diluent for - excipient ingredients: sodium citrate dihydrate; ethanol; water for injections; propylene glycol - for?the?treatment?of?patients?with?multiple?myeloma?for?whom?oral therapy?is?not?appropriate

캐나다 - 영어 - Health Canada

aspen pharmacare canada inc. - melphalan (melphalan hydrochloride); buffer solution - solution - 50mg; 10ml - melphalan (melphalan hydrochloride) 50mg; buffer solution 10ml - antineoplastic agents

필리핀 - 영어 - FDA (Food And Drug Administration)

aspen philippines, inc. - melphalan - tablet, film coated - 2mg

필리핀 - 영어 - FDA (Food And Drug Administration)

s.m.h.p. marketing & consultancy - melphalan - film-coated tablet - 2 mg

유럽 연합 - 영어 - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastic agents - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma.phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults.phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

필리핀 - 영어 - FDA (Food And Drug Administration)

i.e medica inc. - melphalan - film coated tablet - 2 mg

필리핀 - 영어 - FDA (Food And Drug Administration)

i.e. medica inc.; distributor: medethix, inc. - melphalan - film-coated tablet - 2mg